Clinical Trial

RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, single-arm, multicenter clinical study to evaluate the efficacy and safety of chidamide, rituximab combined with lenalidomide sequential immunochemotherapy in the treatment of newly diagnosed elderly double-expressor diffuse large B-cell lymphoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-04.
Status change: Not Yet Recruiting → Recruiting 2024-11-15
Trial Details
NCT Number NCT06674096
Lead Sponsor Zhejiang Cancer Hospital
Conditions Double-expressor Lymphoma
Enrollment 44 participants
Start Date 2024-11-06
Primary Completion 2029-12-30 (estimated)
Study Completion 2030-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-11-18